This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Storb R, Sale G, Barnett T, Yu C, Zellmer E, Little MT . Transient mixed hematopoietic chimerism in dogs given thymic irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 2001; 97: 2915–2916.
Rodriguez R, Parker P, Nademanee A, Smith D, O’Donnell MR, Stein A et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant 2004; 33: 1123–1129.
Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560–565.
Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant 2007; 13: 299–306.
Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12: 573–584.
Preville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460–468.
Klaus G, Mostert K, Reckzeh B, Mueller TF . Phenotypic changes in lymphocyte subpopulations in pediatric renal-transplant patients after T-cell depletion. Transplantation 2003; 76: 1719–1724.
Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465–474.
Zand MS . B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006; 82: 1387–1395.
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756–762.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rodriguez, R., Nademanee, A., Palmer, J. et al. Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD. Bone Marrow Transplant 45, 205–207 (2010). https://doi.org/10.1038/bmt.2009.112
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.112
This article is cited by
-
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT
Bone Marrow Transplantation (2021)
-
A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant
Bone Marrow Transplantation (2013)